DK3519394T3 - Fremgangsmåde til fremstilling af den krystallinske form af modifikation a af calcobutrol - Google Patents

Fremgangsmåde til fremstilling af den krystallinske form af modifikation a af calcobutrol Download PDF

Info

Publication number
DK3519394T3
DK3519394T3 DK17768733.2T DK17768733T DK3519394T3 DK 3519394 T3 DK3519394 T3 DK 3519394T3 DK 17768733 T DK17768733 T DK 17768733T DK 3519394 T3 DK3519394 T3 DK 3519394T3
Authority
DK
Denmark
Prior art keywords
calcobutrol
preparing
modification
crystallinic
crystallinic form
Prior art date
Application number
DK17768733.2T
Other languages
English (en)
Inventor
Johannes Platzek
Wilhelm Trentmann
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of DK3519394T3 publication Critical patent/DK3519394T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/04Calcium compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK17768733.2T 2016-09-27 2017-09-11 Fremgangsmåde til fremstilling af den krystallinske form af modifikation a af calcobutrol DK3519394T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16190812 2016-09-27
PCT/EP2017/072683 WO2018059914A1 (en) 2016-09-27 2017-09-11 Method for producing the crystalline form of modification a of calcobutrol

Publications (1)

Publication Number Publication Date
DK3519394T3 true DK3519394T3 (da) 2020-08-17

Family

ID=57003447

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17768733.2T DK3519394T3 (da) 2016-09-27 2017-09-11 Fremgangsmåde til fremstilling af den krystallinske form af modifikation a af calcobutrol

Country Status (26)

Country Link
US (2) US10793532B2 (da)
EP (1) EP3519394B1 (da)
JP (2) JP7053590B2 (da)
KR (1) KR102395523B1 (da)
CN (1) CN109803958B (da)
AR (1) AR109729A1 (da)
AU (1) AU2017333698B2 (da)
BR (1) BR112019006066A2 (da)
CA (1) CA3038036C (da)
CY (1) CY1123317T1 (da)
DK (1) DK3519394T3 (da)
ES (1) ES2809736T3 (da)
HR (1) HRP20200922T1 (da)
HU (1) HUE050553T2 (da)
IL (1) IL265536B (da)
LT (1) LT3519394T (da)
MX (1) MX2019003540A (da)
NZ (1) NZ751256A (da)
PL (1) PL3519394T3 (da)
PT (1) PT3519394T (da)
RS (1) RS60392B1 (da)
SG (1) SG11201901460UA (da)
SI (1) SI3519394T1 (da)
TW (1) TWI765913B (da)
UY (1) UY37421A (da)
WO (1) WO2018059914A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3519394T3 (pl) * 2016-09-27 2020-11-30 Bayer Pharma Aktiengesellschaft Sposób wytwarzania krystalicznej postaci o modyfikacji a kalkobutrolu
WO2020084504A1 (en) * 2018-10-24 2020-04-30 Biophore India Pharmaceuticals Pvt. Ltd Novel process for the preparation of macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetra azacyclododecane-1,4,7-triyl) triacetic acid and it's complexes with paramagnetic metal ions
CN111039885B (zh) * 2019-12-06 2021-03-05 广州康瑞泰药业有限公司 一种制备高纯度考布曲钙的方法
KR20210112910A (ko) * 2020-03-06 2021-09-15 주식회사 엔지켐생명과학 가도부트롤 주사제 제조를 위한 부형제인 칼코부트롤의 제조 방법
KR20210114742A (ko) * 2020-03-11 2021-09-24 주식회사 엔지켐생명과학 칼테리돌의 제조방법
CN114573522A (zh) * 2020-11-30 2022-06-03 江苏恒瑞医药股份有限公司 一种考布曲钙的新晶型及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1491129A (en) 1975-06-04 1977-11-09 Guerbet Sa Iodo-benzene derivatives and an x-ray contrast medium containing them
US4284620A (en) 1979-03-23 1981-08-18 Mallinckrodt, Inc. N-(2-Hydroxyethyl)-2,4,6-triiodo-3,5-bis-(2-keto-L-gulonamido)benzamide and radiological compositions containing same
NO161560C (no) 1980-04-17 1989-09-06 Univ California Symmetriske trijodisoftaldiamid-derivater og roentgenkontrastmidler inneholdende disse.
DE3150916A1 (de) 1981-12-18 1983-06-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen N-hydroxyaethylierte 2,4,6-trijodaminoisiophthalsaeure-bis- trihydroxybutylamide, deren herstellung und diese enthaltende roentgenkontrastmittel"
US5059412A (en) 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
US5064633A (en) 1984-06-04 1991-11-12 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes, their formulations and use
MX174467B (es) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
DE3625417C2 (de) 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
DE4009119A1 (de) 1990-03-19 1991-09-26 Schering Ag 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
IE910955A1 (en) 1990-03-23 1991-09-25 Yamanouchi Europ Bv Il-6 inhibiting compositions
DE4035760A1 (de) 1990-11-08 1992-05-14 Schering Ag Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5410043A (en) 1991-12-06 1995-04-25 Schering Aktiengesellschaft Process for the production of mono-N-substituted tetraaza macrocycles
DE4237943C2 (de) 1992-11-06 1997-10-23 Schering Ag Verfahren zur Herstellung von Metallkomplexen der N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecan- und N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivate
DE4218744C2 (de) 1992-06-04 1997-11-06 Schering Ag Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe
DE4318369C1 (de) 1993-05-28 1995-02-09 Schering Ag Verwendung von makrocyclischen Metallkomplexen als Temperatursonden
US5358704A (en) 1993-09-30 1994-10-25 Bristol-Myers Squibb Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents
IT1275426B (it) 1995-05-16 1997-08-07 Bracco Spa Recupero del gadolinio e dei suoi agenti complessanti da soluzioni acquose contenenti i loro complessi
DE19724186C2 (de) 1997-06-02 2002-07-18 Schering Ag Verfahren zur Mono- und 1,7-Bis-N-ß-Hydroxyalkylierung von Cyclen und die entsprechenden N-ß-Hydroxyalkyl-1,4,7,10-tetraazacyclododecan-Li-Salz-Komplexe
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
DE102009053171B4 (de) 2009-11-04 2011-07-21 Bayer Schering Pharma Aktiengesellschaft, 13353 Verfahren zur Herstellung des Calcium-Komplexes von Dihydroxy-hydroxy-methylpropyl-tetraazacyclododecan-triessigsäure (Calcobutrol)
LT2896405T (lt) 2011-04-21 2020-03-25 Bayer Intellectual Property Gmbh Didelio grynumo gadobutrolio gamyba
WO2012170676A1 (en) * 2011-06-08 2012-12-13 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
KR101693400B1 (ko) * 2014-09-17 2017-01-05 에스티팜 주식회사 칼코부트롤의 제조방법
CN105037288B (zh) * 2015-07-23 2017-11-03 上海现代制药海门有限公司 一种布醇的制备方法
CN106187930B (zh) * 2016-07-12 2018-10-19 嘉实(湖南)医药科技有限公司 高纯度考布曲钙的制备方法
PL3519394T3 (pl) 2016-09-27 2020-11-30 Bayer Pharma Aktiengesellschaft Sposób wytwarzania krystalicznej postaci o modyfikacji a kalkobutrolu

Also Published As

Publication number Publication date
PT3519394T (pt) 2020-08-03
JP2022071132A (ja) 2022-05-13
MX2019003540A (es) 2019-08-14
CN109803958A (zh) 2019-05-24
AU2017333698B2 (en) 2020-12-24
US20190210979A1 (en) 2019-07-11
CA3038036A1 (en) 2018-04-05
RU2019111919A (ru) 2020-10-29
WO2018059914A1 (en) 2018-04-05
ES2809736T3 (es) 2021-03-05
TWI765913B (zh) 2022-06-01
KR102395523B1 (ko) 2022-05-10
IL265536B (en) 2022-07-01
AR109729A1 (es) 2019-01-16
JP2019534869A (ja) 2019-12-05
SI3519394T1 (sl) 2020-08-31
KR20190040064A (ko) 2019-04-16
PL3519394T3 (pl) 2020-11-30
TW201815771A (zh) 2018-05-01
US11390592B2 (en) 2022-07-19
LT3519394T (lt) 2020-09-25
EP3519394A1 (en) 2019-08-07
AU2017333698A1 (en) 2019-03-07
EP3519394B1 (en) 2020-05-27
JP7053590B2 (ja) 2022-04-12
BR112019006066A2 (pt) 2019-06-18
SG11201901460UA (en) 2019-03-28
UY37421A (es) 2018-01-31
CY1123317T1 (el) 2021-12-31
HRP20200922T1 (hr) 2020-09-18
IL265536A (en) 2019-05-30
CA3038036C (en) 2024-01-23
US10793532B2 (en) 2020-10-06
JP7444914B2 (ja) 2024-03-06
RS60392B1 (sr) 2020-07-31
NZ751256A (en) 2020-05-29
HUE050553T2 (hu) 2020-12-28
RU2019111919A3 (da) 2020-12-28
CN109803958B (zh) 2023-10-31
US20210009534A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
DK3315610T3 (da) Fremgangsmåde til fremstilling af fucosylerede oligosaccharider
DK3292134T3 (da) Metode til dyrkning af akkermansia
DK3294700T3 (da) Fremgangsmåde til fremstilling af limonen-4-ol
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3372585T3 (da) Fremgangsmåde til fremstillingen af en diarylthiohydantoinforbindelse
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3481942T3 (da) Fremgangsmåder til dyrkning af organoider
DK3473621T3 (da) Fremgangsmåde til fremstilling af diphenylmethan-derivat
DK3515990T3 (da) Fremgangsmåde til fremstilling af lignocellulosematerialer
DK3152176T3 (da) Fremgangsmåde til fremstillingen af en cementforbindelse
DK3402773T3 (da) Fremgangsmåde til fremstilling af methanol
DK3798222T3 (da) Krystallinsk form af den frie base af lorlatinib
DK3383436T3 (da) Forbedret fremgangsmåde til fremstilling af indocyaningrønt
DK3519394T3 (da) Fremgangsmåde til fremstilling af den krystallinske form af modifikation a af calcobutrol
DK3191498T3 (da) Fremgangsmåde til fremstilling af 2'-o-fucosyllactose
DK3152022T3 (da) Fremgangsmåde til fremstilling af en gipsplade og den gipsplade som opnås derved
DK3529233T3 (da) Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider
DK3178324T3 (da) Mikrobicid og fremgangsmåde til fremstilling af samme
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3408015T3 (da) Fremgangsmåde til fremstilling af emulsioner
DK3274143T3 (da) Fremgangsmåde til fremstilling af lignocellulosematerialer
DK3397621T3 (da) Fremgangsmåde til fremstilling af 1,1,3-trioxo-1,2-benzothiazol-6-carboxamid
DK3302788T3 (da) Fremgangsmåde til fremstilling af en sorbent
DK3507282T3 (da) Fremgangsmåde til fremstilling af indolcarboxamidforbindelser